Patrick Ott, MD
Enriched profileProfessor of Medicine, Harvard Medical School; Clinical Director, Melanoma Disease Center; Director, Clinical Sciences, Center for Immuno-Oncology; Senior Physician, Dana-Farber Cancer Institute · Dana-Farber Cancer Institute
Patrick Ott is Professor of Medicine, Harvard Medical School; Clinical Director, Melanoma Disease Center; Director, Clinical Sciences, Center for Immuno-Oncology; Senior Physician, Dana-Farber Cancer Institute at Dana-Farber Cancer Institute. OpenAlex indexes 616 publications with 41,494 citations (h-index 82); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Patrick A. Ott, MD, is Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute, Boston, MA. The public record shows 616 publications with 41,494 citations (h-index 82), centered on Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Immune cells in cancer. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 12 companies, 1 NIH-funded awards (2018–2026).
- Most recent indexed publication: 2026 · Nature biotechnology
- Top research focus: Cancer Immunotherapy and Biomarkers
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 12 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 18 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 206.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Sponsor: Compass Therapeutics
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Sponsor: Dana-Farber Cancer Institute
- Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 27 Aug 2026
12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20253 payments
- PFIZER INC.Program year20251 payment
- Merck Sharp & Dohme LLCProgram year20253 payments
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2018–2026 per NIH RePORTER. The latest:
Congress activity
Updated 27 Aug 2026
97 congress contributions (2008–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- A personalized neoantigen vaccine to reprogram the immune landscape of glioblastoma.
ASCO Annual Meeting
ASCO2026Co-author - Phase 1 dose escalation of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies post checkpoint inhibition.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Sensitive detection of cancer antigens enabled by user-defined peptide libraries.
Nature biotechnology
Article2026 - First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell-Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma.
Cancer immunology research
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01An immunogenic personal neoantigen vaccine for patients with melanoma2,931 citations2017
- 02Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma2,764 citations2015
- 03
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/patrick-ott-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/dana-farber-cancer-institute_melanoma-vaccine-progress-and-possibility-activity-7158156922917982209-QVml
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- MD
PhD - Ludwig Maximilians University of Munich, Germany
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksmoconference.org ↗ - Residency
Internal Medicine - Case Western Reserve University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksmoconference.org ↗ - Fellowship
Hematology-Oncology - New York University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksmoconference.org ↗
Editorial & leadership roles
journal and society appointments- Principal Investigator
first-in-human personalized neoantigen vaccine (NeoVax) trial in melanoma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksmoconference.org ↗ - Member
ASCO, AACR, ESMO, SITC (professional/society memberships)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksmoconference.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- Attending Physician
Department of Medicine, Brigham and Women's Hospital, Boston, MA
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗ - Director
Center for Cancer Vaccines, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →statnews.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute